Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

3 Top Earning Performers You Might Want to Buy: Masco Corporation (MAS)

Page 1 of 2

Earnings and earning-related news is the number one catalyst for stock movement. A strong quarter can dictate the direction of a stock for the following three months as can a bad quarter; in the past I have written in detail about such subjects, a domino effect like reaction following a strong quarter. Therefore, I am looking at a few stocks that could continue to trade higher after strong earnings, and present a domino effect trend with long-term gains.

Masco Corporation (NYSE:MAS)This Retailer Keeps Ticking Higher

Shares of Michael Kors Holdings Ltd (NYSE:KORS) traded higher by almost 9% on Tuesday to new all-time highs after reporting earnings. The company posted revenue growth of 70% year-over-year (yoy), beating expectations by almost $100 million and beating the bottom line consensus by $0.23! The company is expanding rapidly, but more important than its expansion was its 41.4% rise in comparable store sales including a 75% rise in North America. This indicates that the company’s growth is not only through expansion, but also growth at existing stores.

In my opinion, Michael Kors has become the perfect momentum stock, one that is fairly valued with a P/E ratio of near 50 and a price/sales of 6.5. To some this may seem expensive, but just compare its fundamental growth to that of other luxury retailers such as Coach; you’ll see it’s not too expensive. The company is growing rapidly and is showing no signs of slowing down, I’d buy!

Small Cap Momentum Stock that is Undervalued

Albany Molecular Research, Inc. (NASDAQ:AMRI) blasted higher by more than 15% after it reported a 44% yoy gain in revenue and almost doubled EPS expectations. The majority of the company’s revenue comes from “contracts”, and this particular segment grew 50% over last year. The margins from this space improved to 18% from 2% last year and now the company is predicting a boost in guidance. This is a very small $200 million company, one that is improving rapidly and is priced cheap with a price/sales of 0.84. The stock has seen large gains over the last year, 120%, but I think it’s very likely that the undervalued stock continues to trade higher. The contributing factor to determine whether or not it will trade higher will be whether or not margins can continue to improve, I think they will.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!